SAGE Therapeutics Inc (NASDAQ:SAGE) Shares Purchased by BlackRock Inc.

BlackRock Inc. boosted its position in SAGE Therapeutics Inc (NASDAQ:SAGE) by 2.8% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,748,713 shares of the biopharmaceutical company’s stock after purchasing an additional 75,246 shares during the period. BlackRock Inc. owned about 5.32% of SAGE Therapeutics worth $503,261,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Ladenburg Thalmann Financial Services Inc. raised its stake in SAGE Therapeutics by 380.5% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,922 shares of the biopharmaceutical company’s stock valued at $351,000 after purchasing an additional 1,522 shares during the period. Amundi Pioneer Asset Management Inc. increased its stake in SAGE Therapeutics by 40.3% in the 2nd quarter. Amundi Pioneer Asset Management Inc. now owns 191,457 shares of the biopharmaceutical company’s stock worth $35,054,000 after acquiring an additional 54,998 shares during the last quarter. Cambridge Investment Research Advisors Inc. bought a new stake in SAGE Therapeutics in the 2nd quarter worth approximately $373,000. River & Mercantile Asset Management LLP bought a new stake in SAGE Therapeutics in the 2nd quarter worth approximately $1,159,000. Finally, Nuveen Asset Management LLC bought a new stake in SAGE Therapeutics in the 2nd quarter worth approximately $113,776,000.

A number of research firms have issued reports on SAGE. Stifel Nicolaus reaffirmed a “buy” rating on shares of SAGE Therapeutics in a research note on Wednesday, November 20th. Royal Bank of Canada reissued a “buy” rating and set a $235.00 target price on shares of SAGE Therapeutics in a research report on Monday, November 25th. Morgan Stanley reissued a “buy” rating and set a $217.00 target price on shares of SAGE Therapeutics in a research report on Sunday, November 24th. HC Wainwright assumed coverage on SAGE Therapeutics in a research report on Wednesday, October 30th. They set a “neutral” rating and a $160.00 target price on the stock. Finally, BidaskClub raised SAGE Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, November 21st. One analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $205.44.

SAGE traded down $0.57 during trading hours on Wednesday, reaching $149.21. 487,894 shares of the company’s stock traded hands, compared to its average volume of 464,841. SAGE Therapeutics Inc has a 52-week low of $79.88 and a 52-week high of $193.56. The firm has a market capitalization of $8.02 billion, a PE ratio of -18.47 and a beta of 2.52. The firm has a 50-day moving average price of $145.51 and a 200 day moving average price of $161.88. The company has a quick ratio of 12.67, a current ratio of 12.67 and a debt-to-equity ratio of 0.03.

SAGE Therapeutics (NASDAQ:SAGE) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($3.48) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($3.41) by ($0.07). SAGE Therapeutics had a negative return on equity of 60.00% and a negative net margin of 12,931.34%. The firm had revenue of $3.57 million during the quarter, compared to analysts’ expectations of $2.52 million. During the same quarter in the prior year, the company posted ($2.63) earnings per share. SAGE Therapeutics’s quarterly revenue was up 35600.0% compared to the same quarter last year. Equities analysts predict that SAGE Therapeutics Inc will post -13.77 EPS for the current fiscal year.

SAGE Therapeutics Company Profile

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).

Featured Article: Balanced Fund

Institutional Ownership by Quarter for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.